Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
Immunovant, a clinical-stage immunology company focused on autoimmune diseases, announced it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026, via a webcast and conference call on May 20, 2026. The company will also provide a business update during the call.